Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
argenx | News
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
SEC Filing | argenx
ELITE 2023 Marketing Team VYVGART Brand Launch Team of argenx | PM360
argenx | News
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Authera lands collaborative agreement with argenx – Inven2
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Argenx, Zai Lab Soar on Promising Data in CIDP - TipRanks.com
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Business Wire
Generalized Myasthenia Gravis Market and Epidemiology 2032:
Argenx: Next Phase Of Growth With Efgartigimod And ARGX-117 (NASDAQ:ARGX) | Seeking Alpha
Latest Healthcare and Pharma Press Release | Latest Healthcare News
Myasthenia Gravis Foundation of America, Inc. - argenx announces positive topline results from Phase 3 ADAPT trial for gMG. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia
Argenx's Potential Blockbuster Gets FDA Nod for Autoimmune Disease
SEC Filing | argenx
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
argenx | News
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
argenx SE (ARGX) Stock Price, Quote & News - Stock Analysis
Genmab expands immunology reach in argenx pact
Karen Gluck - Quality Control Editor - argenx | LinkedIn
argenx Announces U.S. Food and Drug Administration Approval
Argenx gets FDA nod for first subcutaneous gMG therapy | pharmaphorum
Argenx Follows up Phase III Success with Giant €785M Global Offering
argenx | News
